Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 3
Submit an article Journal homepage
71
Views
27
CrossRef citations to date
0
Altmetric
Original Article

A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis

Richard W. Yee Hermann Eye Center, Houston, TX, USACorrespondence[email protected]
,
Michael Tepedino Cornerstone Research Care, High Point, NC, USA
,
Paula Bernstein Allergan, Inc, Irvine, CA, USA
,
Harold Jensen Allergan, Inc, Irvine, CA, USA
,
Rhett Schiffman Allergan, Inc, Irvine, CA, USA
,
Scott M. Whitcup Allergan, Inc, Irvine, CA, USA
& for the Gatifloxacin BID/QID Study Group show all
Pages 425-431 | Accepted 28 Jan 2005, Published online: 03 Mar 2005

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Lorenzo J Cervantes & Francis S Mah. (2011) Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. Clinical Ophthalmology 5, pages 495-502.
Read now
Cindy Hutnik & Mohammad H Mohammad-Shahi. (2010) Bacterial conjunctivitis. Clinical Ophthalmology 4, pages 1451-1457.
Read now
Michael E. Tepedino, Warren H. Heller, Dale W. Usner, Lynne S. Brunner, Timothy W. Morris, Wolfgang Haas, Michael R. Paterno & Timothy L. Comstock. (2009) Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Current Medical Research and Opinion 25:5, pages 1159-1169.
Read now

Articles from other publishers (24)

Muhammad Sohail, Hafiz Muhammad Abd Ur Rahman & Muhammad Nadeem Asghar. (2020) Gatifloxacin–Ionic Surfactant Interactions: Volumetric, Acoustic, Voltammetric, and Spectroscopic Studies. Journal of Surfactants and Detergents 24:2, pages 327-342.
Crossref
Leopoldo Baiza-DuránOscar Olvera-MontañoArieh R. Mercado-SesmaAldo A. Oregon-MirandaAlfredo Lizárraga-Corona, Juan C. Ochoa-Tabares, Ana L. Pérez-Balbuena, Irene M. Montoya-Sánchez, Laura R. Saucedo-Rodríguez, Fernando Mora-González, Pedro A. Gómez-Bastar, Miguel A. Villanueva-Najera, Laura I. Sandoval-Delgadillo, M. González-Lomelí, Juan H. Páez-Garza, Mónica Orozco-Carroll & Mauricio Casillas-Magallanes. (2018) Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. Journal of Ocular Pharmacology and Therapeutics 34:3, pages 250-255.
Crossref
Aiman Abdeltawwab Hashish, Molham Abdelhafez Elbakary & Waleed Abdelhady Allam. (2018) Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study. Journal of Pediatric Ophthalmology & Strabismus 55:2, pages 135-139.
Crossref
Warren HellerMarilou CruzYasmin Rusi BhagatJesse M. De LeonCarlos FelixLinda VillanuevaDavid A. HollanderHarold Jensen. (2014) Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older. Journal of Ocular Pharmacology and Therapeutics 30:10, pages 815-822.
Crossref
Ashok Binjawadgi, Kakkeri R.H.Patil Banderao V, Prashant Dass & Shrinivas Raikar. (2013) DRUG PRESCRIBING PATTERN IN CATARACT SURGERY BY INTRA - OCULAR LENS IMPLANTATION. Journal of Evolution of Medical and Dental sciences 2:35, pages 6723-6732.
Crossref
Patil Banderao V, Ashok Binjawadgi & Prashant Dass. (2013) ROLE OF ANTIMICROBIALS IN INTRA OCULAR LENS (IOL) IMPLANTATION. Journal of Evolution of Medical and Dental sciences 2:26, pages 4852-4860.
Crossref
Jesse DeLeon, Bruce E. Silverstein, Catherine Allaire, Lynne S. Gearinger, Kirk M. Bateman, Timothy W. Morris & Timothy L. Comstock. (2012) Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis in Adults and Children. Clinical Drug Investigation 32:5, pages 303-317.
Crossref
P. J. Mitchell. (2011) Fracture Liaison Services: the UK experience. Osteoporosis International 22:S3, pages 487-494.
Crossref
Bruce E. Silverstein, Catherine Allaire, Kirk M. Bateman, Lynne S. Gearinger, Timothy W. Morris & Timothy L. Comstock. (2011) Efficacy and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study in Adults and Children. Clinical Therapeutics 33:1, pages 13-26.
Crossref
Sarkis H. Soukiasian & Jules Baum. 2011. Cornea. Cornea 521 533 .
Paul Karpecki, Michael R. Paterno & Timothy L. Comstock. (2010) Limitations of Current Antibiotics for the Treatment of Bacterial Conjunctivitis. Optometry and Vision Science 87:11, pages 908-919.
Crossref
Timothy L. Comstock, Michael R. Paterno, Heleen H. DeCory & Dale W. Usner. (2010) Safety and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Conjunctivitis. Clinical Drug Investigation 30:10, pages 675-685.
Crossref
P.-Y. Robert, T. Bourcier, A. Meddeb-Ouertani, M. Khairallah, K. Zaghloul, A. Amraoui, Y. Bhagat, M. Pop & I. Cochereau. (2010) Évaluation de l’efficacité d’un collyre azithromycine 1,5% versus tobramycine 0,3% sur les signes cliniques de la conjonctivite bactérienne purulente. Journal Français d'Ophtalmologie 33:4, pages 241-248.
Crossref
Marguerite B. McDonald, Eugene E. Protzko, Lynne S. Brunner, Timothy W. Morris, Wolfgang Haas, Michael R. Paterno, Timothy L. Comstock & Dale W. Usner. (2009) Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis. Ophthalmology 116:9, pages 1615-1623.e1.
Crossref
Paul Karpecki, Michael DePaolis, Judy A. Hunter, Eric M. White, Lee Rigel, Lynne S. Brunner, Dale W. Usner, Michael R. Paterno & Timothy L. Comstock. (2009) Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clinical Therapeutics 31:3, pages 514-526.
Crossref
F. Denis, C. Chaumeil, P. Goldschmidt, L. Delval, P. Pouliquen, I. Cochereau, D. Chainier & B. De Barbeyrac. (2018) Microbiologic Efficacy of 3-day Treatment with Azithromycin 1.5% Eyedrops for Purulent Bacterial Conjunctivitis. European Journal of Ophthalmology 18:6, pages 858-868.
Crossref
C. Chiquet & M. Labetoulle. (2008) Les fluoroquinolones en ophtalmologie : indications et modalités d’utilisation. Journal Français d'Ophtalmologie 31:8, pages 803-808.
Crossref
Gunnar Høvding. (2008) Acute bacterial conjunctivitis. Acta Ophthalmologica 86:1, pages 5-17.
Crossref
Harold G. Jensen, Henry D. Perry & Eric D. Donnenfeld. 2008. Albert &amp Jakobiec's Principles &amp Practice of Ophthalmology. Albert &amp Jakobiec's Principles &amp Practice of Ophthalmology 207 214 .
Eric Donnenfeld. (2007) Gatifloxacin ophthalmic solution 0.3% in pediatric bacterial conjunctivitis. Pediatric Health 1:2, pages 161-170.
Crossref
Mahendra Singh Rathore & Dipak K. Majumdar. (2017) Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 7:3, pages E12-E17.
Crossref
Francis Mah. (2006) Bacterial conjunctivitis in pediatrics and primary care. Pediatric Clinics of North America 53, pages 7-10.
Crossref
Randall Olson. (2006) Zymar as an Ocular Therapeutic Agent. International Ophthalmology Clinics 46:4, pages 73-84.
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:10, pages i-xii.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.